Trial Profile
Clinical Phase III Study to Monitor the Safety, Tolerability and Efficacy of Subcutaneous Human Immunoglobulin (Octanorm) in Patients With Primary Immunodeficiency Diseases Who Have Completed the SCGAM-01 Trial
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Sep 2019
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Immunodeficiency disorders
- Focus Adverse reactions; Therapeutic Use
- Sponsors Octapharma
- 06 Sep 2019 Status changed from active, no longer recruiting to completed.
- 07 Jun 2019 Status changed from recruiting to active, no longer recruiting.
- 21 Aug 2018 Planned End Date changed from 1 Jun 2018 to 1 Dec 2020.